Comprehensive Overview of Interstitial Lung Diseases: A Guide for Medical Professionals
OthersPage Navigation
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary interstitium. This article provides a comprehensive overview of these complex diseases.
Etiology and Classification
ILDs can be idiopathic or associated with systemic diseases, environmental exposures, or medications. Idiopathic pulmonary fibrosis (IPF) is the most common ILD and is characterized by progressive fibrosis without a known cause. Other ILDs include sarcoidosis, hypersensitivity pneumonitis, and connective tissue disease-associated ILDs.
Clinical Presentation and Diagnosis
Patients typically present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and clubbing. High-resolution computed tomography (HRCT) is crucial for diagnosis. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management
Management strategies depend on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib can slow disease progression. In cases of ILD associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation may be considered in advanced cases.
Prognosis
The prognosis varies widely, depending on the specific type of ILD. IPF typically has a poor prognosis with a median survival of 2-3 years from diagnosis. On the other hand, ILDs associated with connective tissue diseases often have a more favorable prognosis.
In conclusion, ILDs are a diverse group of diseases with varying etiologies, clinical presentations, and prognoses. A thorough understanding of these diseases is essential for their effective management.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge